[go: up one dir, main page]

ATE245168T1 - Peptide, die anti-zellanhaftungsaktivität aufweisen - Google Patents

Peptide, die anti-zellanhaftungsaktivität aufweisen

Info

Publication number
ATE245168T1
ATE245168T1 AT00105572T AT00105572T ATE245168T1 AT E245168 T1 ATE245168 T1 AT E245168T1 AT 00105572 T AT00105572 T AT 00105572T AT 00105572 T AT00105572 T AT 00105572T AT E245168 T1 ATE245168 T1 AT E245168T1
Authority
AT
Austria
Prior art keywords
ala
cell adhesion
peptides
exhibit anti
adhesion activity
Prior art date
Application number
AT00105572T
Other languages
English (en)
Inventor
Katsuhiko Akiyama
Takeshi Goto
Fumio Fukai
Masaaki Ueki
Original Assignee
Hisamitsu Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co filed Critical Hisamitsu Pharmaceutical Co
Application granted granted Critical
Publication of ATE245168T1 publication Critical patent/ATE245168T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00105572T 1999-03-16 2000-03-16 Peptide, die anti-zellanhaftungsaktivität aufweisen ATE245168T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11070127A JP2000264900A (ja) 1999-03-16 1999-03-16 新規生理活性ペプチド

Publications (1)

Publication Number Publication Date
ATE245168T1 true ATE245168T1 (de) 2003-08-15

Family

ID=13422589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00105572T ATE245168T1 (de) 1999-03-16 2000-03-16 Peptide, die anti-zellanhaftungsaktivität aufweisen

Country Status (5)

Country Link
US (1) US6451971B1 (de)
EP (1) EP1036798B1 (de)
JP (1) JP2000264900A (de)
AT (1) ATE245168T1 (de)
DE (1) DE60003860T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601511B2 (en) * 2003-11-12 2009-10-13 University Of Georgia Research Foundation, Inc. Biotin-facilitated transport in gram negative bacteria
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0631316B2 (ja) * 1982-08-04 1994-04-27 ラ ジヨラ キヤンサ− リサ−チ フアンデイシヨン ポリペプチド

Also Published As

Publication number Publication date
DE60003860D1 (de) 2003-08-21
EP1036798B1 (de) 2003-07-16
US6451971B1 (en) 2002-09-17
JP2000264900A (ja) 2000-09-26
EP1036798A1 (de) 2000-09-20
DE60003860T2 (de) 2004-02-05

Similar Documents

Publication Publication Date Title
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
ATE477020T1 (de) Prevention und verringerung von ischemia
NO972930L (no) Fibronectin-adhesjonsinhibitorer
DE60329201D1 (de) Substituierte wt1-peptide
EP0528312A3 (de) Zyklische Peptide und ihre Verwendung
CA2158058A1 (en) Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
EP0333356A3 (de) Hirudin-Peptide
ATE368053T1 (de) Antimikrobielle peptide
ATE332922T1 (de) Antimikrobiell wirkendes peptid
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
ATE245168T1 (de) Peptide, die anti-zellanhaftungsaktivität aufweisen
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
MXPA06014393A (es) Peptidos oligomericos y su uso para el tratamiento de infecciones por vih.
CA2196308A1 (en) Peptide, bronchodilator and blood flow ameliorant
GB0210783D0 (en) Anti-microbial polypeptides
ATE42308T1 (de) Pharmakologisch aktive peptide.
ATE82984T1 (de) Hemmende peptide.
DE60038310D1 (de) Menschliche antithrombin-varianten
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
AU773969C (en) Novel tachykinin peptides, precursor peptides thereof and genes encoding the same
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
DE60325227D1 (de)
WO2003048187A3 (en) Peptides and use thereof in therapeutic agents against hiv infection
CA2030795A1 (en) Novel physiologically active peptide and calcium metabolism-regulating agent comprising said peptide as effective ingredient
ATE305478T1 (de) Topoisomerase-ii inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties